Aesthetic Connect Public Company LimitedSET: TRP🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

Aesthetic Connect Public Company Limited

Telephone

092-316-5595

Website

https://trphospital.com

Email

daranee.d@teerapornhospital.com

Dividend Policy

Dividend Policy

Dividend Payment Policy of Aesthetic Connect Public Company Limited


Aesthetic Connect Public Company Limited has a policy to distribute dividends to shareholders at a rate of not less than 50% of the net profit after corporate income tax and legal reserve (if any) for each year. The company will consider dividend payments by taking various factors into account to maximize shareholder benefits. Such dividend payments must not significantly impact the company's normal operations.However, the dividend payment may be subject to change depending on the company’s performance, financial position, liquidity, business expansion plans, necessity, and other relevant factors. The Board of Directors will determine the appropriateness of the dividend payment based on these considerations.

Any resolution of the Board of Directors approving the dividend payment must be proposed for approval at the shareholders' meeting.

However, in the case of interim dividends, the Board of Directors has the authority to approve the payment if it deems that the company has sufficient profits to do so without adversely affecting its operations. The shareholders shall be informed of such payment at the next shareholders' meeting.

Historical Dividend Payments

This YearLast Year2 Years Ago3 Years Ago4 Years AgoMetricDescriptionRemark
0.250.40.691.040.43Net profit per share (Baht : Share)Net profit per share (baht : share)
0.250.20.41.030.4Dividend per share (Baht : Share)Dividend per share (baht : share)
00000Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
00000Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
0.250.20.41.030.4Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
94.5550.2372.798.893.36Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)
- In 2025, the Company reported a net profit of Baht 87,199,538.63. The Company is in the process of proposing to the Annual General Meeting of Shareholders for approval of a dividend payment for the 2025 operating results. The dividend will be paid in cash at a rate of Baht 0.25 per share, based on 350,000,000 registered shares, less 20,206,800 treasury shares, resulting in 329,793,200 eligible shares for dividend payment. The total dividend payment amounts to Baht 82,448,300. All dividends will be subject to withholding tax at the rate prescribed by law. The Company will pay the dividends to shareholders whose names appear on the Record Date on 12 May 2026, with the dividend payment scheduled for 27 May 2026. - On 9 February 2023, the Company resolved to change the par value of its ordinary shares from Baht 10 per share to Baht 0.50 per share. Therefore, for the years 2021–2022, the number of shares has been recalculated based on the par value of Baht 0.50 per share for comparison purposes.

Major Shareholders

Major Shareholders

No.NameShares% Shares
34,408SAN FUN HOLDING CO., LTD.118,800,00033.94
34,409CDR. SUWANNEE JIRAYANGYUEN80,000,00022.86
34,410Aesthetic Connect PCL20,206,8005.77
34,411MR. KRITAPAS JIRAYUNGYURN12,514,2003.58
34,412MR. SUPAKORN JIRAYUNGYURN8,015,0003.58
34,413MR.VITHIT PONGPIRODOM5,871,4011.68
34,414MR. VORADORN ATHICHALINTHORN5,846,7001.67
34,415MR. KHANTI WIWATWISAWAKORN3,495,9801
34,416MISS JUTIMA PATLIDANON3,460,0000.99
34,417MRS.CHARASSRI PONGPIRODOM3,391,2000.97
34,418MISS SUVIMOL JIRAYUNGYUEN3,300,0000.94
34,419MISS NUTTHA JIRAYANGYUEN3,042,6000.87
34,420MR.SUMETH JIRAYANGYUEN3,030,8000.86
34,421MR. PALAPONG CHAYANGSU3,000,0000.86
34,422MRS.SUWANNA JIRAYANGYUEN3,000,0000.86
34,423MR. CHAIYOT DENARIYAKUL2,679,3000.77
34,424MISS SARINYA URATHAMAKUL2,449,7000.7
34,425MR.SITTHIKORN LAOCHAREONWANIT1,924,2000.55
34,426MR. KONGSAK TECHAWIBUNPHON1,815,0000.52
34,906MR.PAIBOON SEREEWIWATHANA1,732,6000.5

Business Strategies Overview

Chairman's Message

In 2025, Aesthetic Connect Public Company Limited (“TRP” or the “Company”) faced challenges arising from economic factors at both the global and domestic levels. These included volatility in the global economy resulting from monetary policies of major economies, geopolitical tensions in several regions of the world, and economic slowdowns in certain countries. At the same time, the domestic economy continued to face constraints from high levels of household debt and uncertainties in the economic and political landscape, which affected consumer confidence and the overall investment climate. Nevertheless, the healthcare and beauty industry continues to demonstrate steady growth, driven by increasing consumer awareness of health, quality of life, and personal image. Under these circumstances, the Company has adjusted its business strategies to align with the changing economic environment by focusing on enhancing the quality of medical services, strengthening the capabilities of its physicians and medical personnel, and adopting medical technologies and innovations to improve service efficiency and deliver better experiences for clients.

The Company officially commenced operations of Teeraporn Hospital on 26 June 2025, marking another significant milestone in the Company’s business development. Previously operating as an aesthetic surgery clinic, the Company has upgraded its services to a specialized hospital providing aesthetic surgery and holistic healthcare services. Teeraporn Hospital is located on Somdet Phra Chao Taksin Road, Thon Buri District, Bangkok. The facility is a five-storey building with approximately 9,918 square meters of usable space, equipped with 12 standard operating rooms, 9 consultation rooms, and a multidisciplinary team of specialized physicians to accommodate the continuously increasing number of patients and to further enhance treatment standards in terms of safety and efficiency. In addition, the Company places importance on developing preventive healthcare and anti-aging medicine services to respond to the growing consumer trend toward holistic health care. This is delivered through the TRP Longevity, which focuses on in-depth health screening, anti-aging treatments, and health restoration programs, aiming to promote sustainable well-being and improve the quality of life of its clients.

Furthermore, the company received a 4-star "Very Good" rating in the Corporate Governance Report of Thai Listed Companies 2025 (CGR 2025). This recognition reflects the company’s excellence in corporate governance, emphasizing the importance of all stakeholders while conducting business based on principles of integrity and good governance. The company remains committed to sustainable growth and development, driven by a vision to create a positive impact on society.

Lastly, on behalf of the Board of Directors, we would like to express our sincere gratitude to all medical personnels, executives, employees, shareholders, partners, customers, and all stakeholders for their support, trust, and valuable advice throughout the past year. We sincerely hope to continue receiving your support in the future. The Board of Directors is committed to conducting business with prudence, transparency, good governance, and ethical business practices to ensure the company’s stable and sustainable growth in the long term.

Prof. Dr. ApichatiSivayathorn

Chairman

Aesthetic Connect Public Company Limited

Message from the Chief Executive Officer

The year 2025 marked a significant milestone for Aesthetic Connect Public Company Limited (“TRP”), a provider of aesthetic medical services under the “Teeraporn” brand. During the year, the Company successfully upgraded its operations from a clinic to Teeraporn Hospital, thereby enhancing its service capabilities to a comprehensive hospital level. Since July 2025, the Company has provided specialized services in facial plastic surgery, wellness and longevity, and breast and body procedures. The hospital is located on Somdet Phra Chao Taksin Road and is equipped with expanded facilities and modern medical infrastructure to support the delivery of integrated and high-quality services that effectively respond to the diverse needs of patients.

Teeraporn Hospital is committed to delivering an enhanced patient experience in all dimensions, including facilities, convenience, and service excellence, while maintaining high medical standards at reasonable and appropriate pricing. The Company places strong emphasis on ensuring that patients feel valued and well cared for, fostering long-term trust and satisfaction. These principles have been consistently upheld for over 40 years and remain a cornerstone of the Company’s operations.

In 2025, the Company continued to expand its comprehensive range of aesthetic and medical services to accommodate increasing and diverse patient demands. The Company implemented integrated marketing strategies through both online and offline channels to effectively reach domestic and international customers. The hospital appointed Ms. Khemanit Jamikorn (Pancake) as Brand Ambassador, supported by presenters including well-known celebrities, artists, and influencers with extensive reach. Following the commencement of hospital operations in the third and fourth quarters, patient response showed a positive and continuous improvement.

The Company also continued to prioritize innovation and the development of medical knowledge and service offerings. During the year, the Company introduced a new product, “Multi Cells,” which utilizes patients’ own adipose tissue processed through proprietary techniques developed by Teeraporn Hospital. This innovation provides a safe alternative to synthetic fillers and contributes to natural facial rejuvenation. Multi Cells can be integrated with various surgical procedures, including facelift surgery, eyelid surgery, rhinoplasty, and chin augmentation. The product has received strong market acceptance, particularly in the fourth quarter.

With respect to Wellness and Longevity services, the Company has further strengthened integration between surgical and preventive healthcare services, while expanding its product offerings to attract new customer segments and support long-term growth.

Furthermore, on 12 February 2026, Teeraporn Hospital was awarded international accreditation under the International Accreditation Standards for Healthcare Organizations (AACI) Version 6.0 (United States), together with ISO 9001:2015 and ISO 7101:2023 certifications, as well as the High Reliability Degree Award, recognizing organizations that consistently demonstrate excellence in operational standards. These achievements reaffirm the Company’s leadership in facial plastic surgery in Thailand, built upon more than 40 years of experience, with a continued focus on quality, safety, and service excellence.

On behalf of the management, we would like to express our sincere appreciation to shareholders, patients, and all stakeholders for their continued trust and support. The Company remains firmly committed to further developing Teeraporn Hospital to achieve sustainable growth, while upholding ethical standards, medical professionalism, and creating long-term value for society.

Associate Professor Dr.Choladhis Sinrachtanant

Chief Executive Officer

Aesthetic Connect Public Company Limited

Vision

An institution that provides surgery, rehabilitation, and total facial care solution for sustainable beauty and global quality.

Mission

Providing care and treatment with professionalism for both Thai and foreigners. Through the development of knowledge in care and treatment to further develop products and academics. Including providing services to society together with developing health products that can be distributed through other channels with international standards in order to be a leader in innovation related to facial beauty.

Values

I. Clients are relatives.

II. Professionalism is key.

III. Innovation.

IV. Staff is family.

Objectives

The Company is committed to delivering excellent services at international standards through the continuous development of personnel and medical knowledge. This commitment enables the Company to provide innovative products and services that address beauty from the inside out, while contributing to society with responsibility.

Goals

The Company is committed to enhancing its organizational structure and proactively expanding its product portfolio to support the growth of service capacity following the opening of the new hospital, while advancing excellence in standards and strengthening its reputation at the international level.

Business Strategies

1) Service development with modern medicine and innovations. In operating our business for over 10 years, the company recognizes the importance of customer safety. We focus on providing safe and highly effective services with modern medical technologies and innovations. The company keeps abreast of medical innovations and is always looking for state-of-the-art tools to serve our customers. The company selects service tools that are recognized and inspected by the U.S. Food and Drug Administration (US FDA) and the Food and Drug Administration (FDA) of Thailand, which have been tested and proven safe to ensure that customers receive satisfactory service at all times.

2) Physician team development. As the cosmetic surgery business is highly competitive, the development of surgical techniques is constantly and rapidly changing. Therefore, the company places great importance on the development of its medical team and personnel, starting with the recruitment of physicians and medical personnel with experience, ability, and expertise in both specific and various fields. They are able to learn new medical techniques to develop their potential and support the increasing diversity of customer needs who want beautiful, natural results with less downtime compared to traditional surgery. We support our medical team to conduct research and attend international conferences to build a reputation and confidence that our medical team is a leader in facial surgery in the Asian region.

3) Building brand awareness and recognition. As the beauty and cosmetic surgery business is quite competitive and is gaining popularity, brand awareness and building a brand that impresses consumers is extremely important. The company therefore focuses on creating communications that reach the target group in a variety of attractive ways through both offline and online media, giving doctors a greater role in online media. We also focus on providing a good service experience from consultation to aftercare service.

4) Marketing communications to create brand awareness and recognition for products and services. The company has focused on digital marketing, covering SEO, SEM, Google Ads, as well as communication through social media channels on almost every platform, whether it be YouTube, Facebook, Instagram, Tiktok, Lemon 8, or Line Official Account, with a variety of attractive content. This includes co-developing content with celebrities such as actors, models, celebrities, and beauty bloggers with a large following to create awareness and encourage interest in using the company's services. There is also communication through offline media. The company focuses on measuring and evaluating the effectiveness of each form of communication and each channel systematically in order to develop and maximize the return on investment for the business.

5) Expansion of service scope. The company places importance on the diversity of services to accommodate the different needs of customers. We focus on providing comprehensive beauty services, including cosmetic surgery such as facelifts, double eyelid surgery, rhinoplasty, facial contouring, Botox, Filler, and skincare. Most recently, we opened the "TRP Longevity ", which provides modern holistic anti-aging and wellness services based on medical principles. In addition, the company is committed to continuously researching and developing surgical technologies and innovations in order to meet the needs of customers in the ever-changing era.

6) Price-Based Marketing Promotion.Due to the highly competitive nature of the aesthetic and plastic surgery industry, the Company places importance on price-based marketing strategies to attract customers to its services. The key marketing strategies are as follows:

  1. KOL, Influencer, and Celebrity Marketing: Target specific customer segments effectively, build credibility and trust, stimulate faster purchasing decisions, and increase followers across the brand’s platforms.

  2. Pricing Strategy: Set pricing tailored to different customer segments, including general customers and review-based customers, as well as pricing based on the expertise of each physician.

  3. Customer Retention: Encourage repeat purchases by utilizing personalization, including recommending content that aligns with customers’ interests.

  4. Value-Based Marketing: Focus on sustainability-oriented branding and use marketing as a tool to raise social awareness.

  5. Brand Awareness Strategy: Leverage television programs, news websites, and out-of-home (OOH) media to enhance brand recognition on a broader scale.

  6. Expanding Customer Target: Introduce new products and services to attract new customer segments.

Material Changes & Developments

Material Changes & Developments

YearDescription
2,016

- Aesthetic Connect Company Limited was founded by Cdr.Suwannee Jirayangyuen and family, with a registered capital of 5 million baht. The company operates a medical clinic business under the name "Teeraporn Clinic" to provide facial cosmetic surgery services to the public, such as facelifts (Face-Lock), double eyelid surgery, rhinoplasty, and skincare. The clinic is operated by a team of specialized and experienced doctors with more than 10 years of experience, led by Assistant Professor Dr. Choladhis Sinrachatanant, former president of the Facial Plastic Surgery Society of Thailand, as the Chief Executive Officer.

2,019

- The listed company increased its registered capital from 5 million baht to 100 million baht by issuing and offering 95 million baht worth of newly issued ordinary shares to existing shareholders proportionally (Right Offering). The company will use the proceeds from this capital increase to expand its business.

- The company invested the proceeds from the capital increase to purchase land in the Khlong San district (“Plot 1”), with a size of 0-3-85 rai, to prepare for the expansion of service areas to accommodate the increase in service users, in line with the company's business plan.

- The company has started to increase its marketing through online media in foreign countries such as Cambodia, Laos, and Myanmar.

2,021

- The listed company increased its registered capital from 100 million baht to 130 million baht by issuing and offering 30 million baht worth of newly issued ordinary shares to existing shareholders in proportion to their shareholdings (Right Offering) to support business expansion. The group of shareholders, namely Cdr.Suwannee Jirayangyuen and her family, waived their rights to subscribe for the capital increase in proportion to their entitlement, resulting in other shareholders receiving an increased right to purchase additional shares. This is to boost the morale of those involved or those who are instrumental in creating benefits for the company both directly and indirectly. After the capital increase, the group of shareholders, namely Cdr.Suwannee Jirayangyuen and her family, will have a combined shareholding in the company reduced to 76.92 percent. The offering price is a fair price assessed by an independent financial advisor (IFA) approved by the SEC.

- The company has approved the sale of land plot No. 1 due to a significant increase in the number of facelift patients. As a result, the company has considered selling and purchasing a new land plot with sufficient usable space for future use. Therefore, land plot No. 1 is listed as an investment property in the cash flow statement.

- Certified to ISO: 14064-1 standard.

2,022

- The company invested in land acquisition in the Thonburi area ("Plot 2"), sizing 2-2-83 rai, to prepare for the expansion of service areas to accommodate the increase in service users, in line with the company's business plan.

- The company approved the development of Plot 2 for the construction of a hospital building with a usable area of approximately 9,918 square meters (an increase from the current service area of 1,157 square meters), with completion scheduled for the fourth quarter of 2024.

- Received ISO: 14064-1 certification.

2,023

- The Extraordinary General Meeting of Shareholders No. 1/2023 held on February 9, 2023, resolved as follows:

1) Approval of the transformation from a private limited company to a public limited company.

2) Changed the par value from 10.00 baht per share to 0.50 baht per share.

- The Annual General Meeting of Shareholders for the year 2023 held on March 16, 2023, resolved as follows:

1) Increased registered capital by 45,000,000 baht from 130,000,000 baht to 175,000,000 baht by issuing 90,000,000 ordinary shares with a par value of 0.50 baht per share for the initial public offering (IPO).

- First traded on the Stock Exchange on October 24, 2006 with an IPO price of 14 baht.

- Achieved ISO : 14064-1 certification.

2,024

- The Company signed a business cooperation agreement with Khongkwan Clinic Company Limited (KKC Clinic) on March 12, 2024.

- "Corporate Governance Assessment of Listed Companies for 2024" The company received an "Excellent" (5-Star) rating in the Corporate Governance Report of Thai Listed Companies (CGR) from the Thai Institute of Directors (IOD), reflecting its strong commitment to corporate governance practices.

- Evaluation of the Quality of the 2024 Annual General Meeting of Shareholders" On April 25, 2024, the company received an evaluation score of 92 out of 100 from the Thai Investors Association (TIA). This score reflects the transparency and efficiency of the company in organizing the shareholders' meeting.

- Opened the TRP Longevity , providing holistic health consultations, located on the 3rd floor of Teeraporn Clinic. The center has specialized physicians in anti-aging medicine to provide consultations on common problems associated with aging, such as fatigue, insomnia, hormonal imbalances, and age-related diseases. The physicians will provide personalized consultations and advice tailored to each individual's needs.

- Certified to ISO: 14064-1 standard.

2,025
  • On February 21, 2025, the Board of Directors’ Meeting No. 1/2025 resolved to approve the Company’s share repurchase program for financial management purposes (Treasury Stock) with a total budget not exceeding Baht 120 million and a maximum of 14,000,000 shares to be repurchased, representing 4.00% of the Company’s total issued and paid-up shares, which does not exceed 10% of the total issued shares. The share repurchase will be conducted through the Stock Exchange of Thailand’s trading system during the period from March 3, 2025 to September 2, 2025.

  • On July 6, 2025, the Company officially held the Soft Opening ceremony of “Teeraporn Hospital.” The event was filled with a warm atmosphere, smiles, and memorable moments, attended by distinguished guests, celebrities, and prominent figures from various industries, as well as family members and related parties who joined in celebrating this significant occasion. This event marked another memorable milestone for the Company.

  • The Company has been rated 4 stars, or “Very Good,” in the Corporate Governance Report (CGR) by the Thai Institute of Directors (IOD). This reflects the Company’s strong commitment to good corporate governance and transparency.

  • The quality assessment of the Annual General Meeting of Shareholders for the year 2025, held on August 6, 2025, resulted in the Company receiving a score of 97 out of 100 from the Thai Investors Association (TIA). This reflects the Company’s transparency and efficiency in organizing shareholders’ meetings as a listed company.

  • On August 14, 2025, the Board of Directors’ Meeting No. 3/2025 resolved to approve an amendment to the share repurchase program, increasing the maximum number of shares to be repurchased from not exceeding 14,000,000 shares to not exceeding 21,000,000 shares, within the same budget of not exceeding Baht 120 million. The revised number of shares represents 6.00% of the Company’s total issued and paid-up shares, which does not exceed 10% of the total issued shares.The method and duration of the Company’s share repurchase program for financial management purposes (Treasury Stock) remain unchanged in accordance with the TS-1.2 form dated February 21, 2025, as

  • Achieved ISO : 14064-1 certification.

Use of Proceeds from Securities Offerings

Introduction

The company received fundraising proceeds from the stock exchange, with a remaining amount of 1,215.28 million baht after deducting offering expenses. The details of fund utilization as of December 31, 2025, are as follows:

Is There Money Raised from a Securities Offering Still to Report On?

Yes

Offerings

Type of SecuritiesAmount Raised Given AsAmount Raised (Million Baht)Uses of the MoneyUsed as Declared?Progress / Reasons and Measures if Not Used as DeclaredRelated Link
Equity Instruments28731,215.282026-12 · Objective: 1. Investment in hospital construction projects · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 522.59 · Expected amount type: 2873 · Start expected amount range: 550.0 · 2026-12 · Objective: 2. Procurement of Medical Equipment and Devices · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 29.76 · Expected amount type: 2873 · Start expected amount range: 80.0 · 2023-10 · Objective: 3. Repayment of Loans from Financial Institutions · Period type: 2871 · Start period: 2023-10 · Spent amount type: 2873 · Start spent amount: 95.44 · Expected amount type: 2873 · Start expected amount range: 95.44 · 2026-12 · Objective: 4. To be used as working capital for business operations, other investments, and business expansion (if any) · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 5.17 · Expected amount type: 2873 · Start expected amount range: 489.84N

At the Board of Directors’ Meeting No. 4/2025, held on November 7, 2025, a resolution was passed to approve the extension of the utilization period for the proceeds from the initial public offering (IPO). This was due to the expected delay in the inspection and final payment for the hospital construction project, including retention payments, which are anticipated not to be completed by December 31, 2025.

In addition, the procurement of certain medical equipment, such as a hyperbaric chamber and J-Plasma devices, is planned for 2026.

https://weblink.set.or.th/dat/news/202501/1836NWS240120251704150401E.pdf?_gl=1*1vugo0h*_gcl_au*NTU2NzgwMjE2LjE3MzQzMzg3ODc.*_ga*OTU0MTY5NTY1LjE3MTg2MDc2Njg.*_ga_ET2H60H2CB*MTc0MTU4NjEwOC4yNTMuMS4xNzQxNTg2OTg0LjI3LjAuMA..

Law Governing the Debt Securities

-The company does not offer debt securities.-

Commitments Made in the Registration Statement

Are There Commitments or Conditions from an Offering or Listing?

No

Group Operating-Structure Policy

Description


None


Shareholders with Potential Conflict of Interest

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Relationship Exists (Y/N)

No

Shareholders' Agreement

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Introduction

he shareholding structure applies only to Aesthetic Connect Public Company Limited, as there are no subsidiaries or associated companies. As of December 29, 2025, the shareholding structure comprises the Jirayangyuen family, which is grouped based on the surname and publicly available information, without considering any relationships or actions that might fall under joint actions with other individuals, in accordance with the Securities and Exchange Commission’s announcement No. T.J. 7/2009. The "group of doctors" refers to physicians working at the Teeraporn Hospital, excluding those within the Jirayangyuen family.

Does the company hold shares in other companies?

No

Income Structure

Introduction

From 2023 to 2025, the company generated operating revenues of 713.03 million baht, 554.74 million baht,and 481.58 million baht, respectively. The details are as follows:

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations481,578.37100554,739.47100713,023.28100
Surgical Services424,578.1488.16487,209.8487.83657,785.1392.25
Intravenous Anesthesia Services20,481.24.2523,5254.2430,5304.28
3. Non-Surgical Services26,386.475.4822,917.744.1319,5102.74
OtherOthers9,879.662.0521,086.893.85,198.150.73

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue481,578.37100554,739.47100713,023.28100
DomesticDomestic481,578.37100554,739.47100713,023.28100
InternationalInternational000000

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 9879.66 · Description: Total other income · As of yesteryear: 21086.88 · As of year before yesteryear: 5198.15 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01712 · As of year: 9879.66 · Description: Other income not from operations · As of yesteryear: 21086.88 · As of year before yesteryear: 5198.151713 · As of year: 0.0 · Description: Share of profit · As of yesteryear: 0.0 · As of year before yesteryear: 0.0

Product / Service Characteristics

Introduction

The Company operates a healthcare facility under the name “Teeraporn Hospital,” providing aesthetic surgery services to the general public. The Company offers comprehensive facial aesthetic solutions in one place, addressing all aspects of facial surgery needs. It has long been recognized as one of the leading providers of double eyelid surgery, as well as for its proprietary facelift technique (Face-Lock), which is exclusively available at Teeraporn Hospital.

The Company’s core services can be categorized into three main types, as follows:

Business Type

3115

Business Groups

Business GroupDescription
1.Surgical procedure services

The company provides surgical procedures that adhere to medical standards, including surgeries requiring intravenous anesthesia under the supervision of expert anesthesiologists. This ensures patient safety and minimizes post-surgical complications. The primary services include:

1.Face-Lock Facelift Surgery

The Face-Lock facelift technique is a surgical innovation developed by Associate Professor Dr. Choladhis Sinrachtanant and the team of surgeons at Teeraporn Hospital. This technique lifts and tightens all areas of the face, from the forehead to the lower face, reducing sagging and wrinkles while harmonizing facial contours for a youthful appearance. The "Lock System of Teeraporn Hospital" is a groundbreaking facelift technique refined over 20–30 years of research, specifically designed for Asian facial structures. The procedure leaves minimal scars, results in less swelling and bruising, and allows patients to return home immediately without requiring a recovery period.

2.Eye Surgery

2.1 Double Eyelid Surgery (Lucky Eye) with Eye-Lock Technique

The Eye-Lock technique, exclusive to Teeraporn Hospital, was developed by Associate Professor Dr. Choladhis Sinrachtanant and his medical team. Recognized globally, this technique has been featured in books such as "Less is More My Way" and "Asian Blepharoplasty." It has set the standard for short-incision double eyelid surgery, ensuring aesthetically pleasing results while maintaining strict medical standards.

The hospital also offers customized surgical corrections for various eyelid conditions, including upper eyelid muscle adjustments.

2.2 Ptosis Surgery

Ptosis, or drooping eyelids, occurs due to weakened eyelid muscles, leading to visual impairment, eye strain, fatigue, and reduced confidence. Teeraporn Hospital provides medically standardized treatments using a short-incision technique to minimize scarring and accelerate recovery while delivering noticeable results.

2.3 Deep-Set Eye Correction with Fat Augmentation

This procedure addresses deep-set eyes caused by congenital fat deficiency or age-related fat loss. The hospital utilizes fat grafting from the abdomen, to restore volume to the eyelids while complementing double eyelid surgery.

2.4 Additional Eye Surgery Services

These include correction of hidden eyelids, asymmetrical eyelids, multiple eyelid folds, excess eyelid skin removal, under-eye bag surgery, and revision double eyelid surgery from prior unsuccessful procedures at other clinics.

3.Rhinoplasty Surgery

Teeraporn Hospital offers expert consultation and a variety of rhinoplasty techniques tailored to each client's needs. The most common techniques include:

3.1 Silicone and Artificial Tissue Rhinoplasty

This method uses Megaderm (a collagen-based artificial tissue) to reinforce the nasal tip, preventing complications such as thin nasal skin or implant extrusion. This technique is ideal for individuals with thin nasal skin who want a more projected nose tip without harvesting ear cartilage.

3.2 Autologous Fat Grafting Rhinoplasty

Developed by Associate Professor Dr. Choladhis. Sinrachatanant 1993, this technique uses fat extracted from the thighs or lower abdomen to enhance the nose naturally. It was created as an alternative to liquid silicone injections, which often led to deformities. This method improves nasal shape while avoiding foreign materials, making it ideal for patients with silicone allergies or previous nasal implant complications.

Associate Professor Dr. Choladhis and his team have compiled their expertise in "Masterclass Rhinoplasty," a resource for advancing surgical education in rhinoplasty.

3.3 Nose Surgery with Structural Modification Technique (Open Nose Reconstruction) Nose surgery with the structural modification technique focuses on correcting and adjusting the structure of the nose to be balanced and proportionate to the individual's physique. The procedure uses the Open Rhinoplasty technique, which involves making an incision at the base of the nose, allowing the surgeon to clearly view the internal structure of the nose. This enables the surgeon to resize the nasal base, adjust the shape of the nose to appropriate proportions, and refine the nasal tip for a slimmer appearance. This type of surgery is suitable for individuals who need to alter their nasal structure in a way that cannot be corrected using the closed rhinoplasty technique, which only involves the use of silicone or synthetic medical materials. A key feature of nose surgery with the structural modification technique is the ability to use various materials, not just synthetic materials. The surgeon can also use materials taken from the patient’s own body, which are safer and reduce the risk of adverse reactions from the body. The materials that can be used to modify and reconstruct the nose include:

• Septal Cartilage – This is a flat, straight, smooth, and strong cartilage found in the middle septum of the nose. It is the only area in the body suitable for augmenting the nasal tip.

• Ear Cartilage – This is used when the septal cartilage is too small and insufficient for nasal tip enhancement.

• Rib Cartilage – This is used when the septal cartilage is too small, and stronger cartilage is required for structural enhancement, especially at the nasal tip.


4. Additional Cosmetic Surgeries

In addition to the surgical services mentioned above, the Company also provides other aesthetic surgical procedures, including brow lift surgery (Brow Lock), sub-brow lift surgery (Sub Brow Lock), neck lift surgery (Neck Lock), chin augmentation, forehead lift surgery (Forehead Lock), hair transplantation, breast surgery, and body contouring surgery.

Investors or interested persons may find further information on the Company’s website.

2. Anesthesia Services

Teeraporn Hospital places the highest priority on the safety and comfort of its patients. An anesthesiologist closely monitors patients throughout the surgical procedure. The Hospital provides two main types of anesthesia services, as follows:

2.1 Intravenous Sedation (Sedation):
Used for minor surgeries or non-complex procedures, where the anesthesiologist administers an appropriate level of sedative medication through an intravenous line.

2.2 General Anesthesia:
Used for procedures that require a deeper level of anesthesia or involve longer surgical durations.

3.Non-surgical services

In addition to the aforementioned services, the Company also provides non-surgical treatments, including skin and aesthetic services. The key services are as follows:

3.1 Anti-wrinkle injections and facial contouring (Botox)
Botox, or Botulinum toxin type A, is a substance derived from the bacterium Clostridium botulinum. When injected, it acts on the nervous system (neurotoxin), temporarily reducing muscle activity. This helps diminish wrinkles and deep lines within a short period, such as those on the forehead, glabella, and crow’s feet, as well as contouring the face by reducing jaw muscles. Results are typically visible within 3–14 days after injection.

3.2 Dermal fillers for wrinkle reduction and facial contouring (Filler)
Fillers are composed of Hyaluronic Acid (HA), a substance naturally found in the body, allowing it to be safely broken down over time. Fillers are used to restore volume, smooth deep lines, and enhance facial contours, resulting in a fuller and more youthful appearance. They also help retain moisture, improving skin hydration and reducing wrinkles. The effects typically last approximately one year.

3.3 High-Intensity Focused Ultrasound (HIFU)
HIFU stimulates collagen production in all layers of the skin, promoting tissue regeneration. The newly formed tissue is firmer and more compact, resulting in tighter skin, improved pores, smoother texture, and reduced wrinkles, particularly around the neck. Results can be seen from the first treatment and help prevent future skin sagging.

3.4 Ultherapy (Non-surgical lifting treatment)
Ultherapy provides a non-invasive lifting effect by stimulating collagen production deep within the SMAS layer, the same layer targeted in surgical facelifts. This process tightens the skin structure, resulting in firmer and more lifted facial contours.

3.5 Cold fiber laser treatment (UltraClear)
UltraClear is designed for skin rejuvenation, wrinkle reduction, acne scar treatment, and facial tightening. It operates at a wavelength of 2,910 nanometers, allowing precise penetration from the epidermis to the dermis for targeted treatment.

3.6 Skin brightening vitamin therapy
Vitamin injections, including Vitamin C, B1, B6, B12, and amino acids, help repair and revitalize weakened skin cells. These concentrated natural extracts also help inhibit oxidation processes and reduce melanin production, resulting in brighter, healthier skin. Redness may improve within approximately 3 days. This treatment is suitable for all skin types.

3.7 Other skin care services
The Company also offers additional treatments such as LED light therapy, collagen injections, and other facial treatments.

3.8 Anti-aging and wellness services
These services focus on health restoration and rejuvenation, including immune system assessments and vitamin therapies administered via injection or oral supplements to enhance overall well-being.

Research & Development

Has R&D Policy (Y/N)

Yes

Introduction

The company places great importance on and actively promotes research and development of new products to enhance its capability in delivering innovations and new offerings that meet the needs of customers both now and in the future. This initiative strengthens the company’s image as an industry leader while also improving internal processes to ensure operational efficiency and agility. These details are disclosed in the sustainability management report under the social dimension.

R&D Cost — Description

Product and Service Development

In 2025, Aesthetic Connect Public Company Limited (the “Company”) continued to focus on the development of its products and services to support its transition into a specialized hospital for aesthetic surgery, as well as to better address increasingly diverse customer needs. The Company enhanced its core strengths in facial aesthetic surgery, particularly facelift procedures (Face-Lock), eye surgery, and rhinoplasty, through the adoption of advanced medical technologies and treatment techniques. This was complemented by the continuous development of its team of specialist physicians through research and participation in international academic conferences, ensuring that treatment standards are aligned with global benchmarks.

In addition, the Company developed new procedures to cater to specific customer segments, particularly the Silver Age group, which has strong purchasing power. These services focus on targeted treatments such as lower blepharoplasty, correction of ptosis, and alternative rhinoplasty techniques using fat grafting or other substitute materials.

On the service side, the Company has upgraded its standards across all dimensions to align with hospital-level operations. Continuous training has been provided to personnel in areas such as service delivery, consultation, and sales. The Company has also implemented information technology systems to enhance customer management efficiency and improve the overall patient experience.

At the same time, the Company has implemented proactive marketing strategies by integrating efforts between its medical and marketing teams to develop educational content on aesthetic surgery and enhance brand awareness through both online and offline channels. The Company has also begun to expand its international customer base, focusing on countries in Southeast Asia such as Malaysia, Singapore, and Indonesia, as well as the United States. Online platforms and the Company’s website have been upgraded to support multiple languages, increasing accessibility for international clients.

The Company has further developed customer access channels through agency networks in each target country, along with providing training to ensure agents have a clear understanding of the Company’s products and services. Comprehensive services, including accommodation and transportation arrangements, are also provided to enhance the experience of international clients. This approach is expected to encourage word-of-mouth referrals, which the Company believes to be an effective and sustainable marketing strategy in the long term.

In terms of service expansion, the Company places importance on diversifying its offerings to better meet customer needs. In addition to facial surgery, the Company has expanded into other procedures such as breast surgery and liposuction, as well as anti-aging services, to strengthen its comprehensive service capabilities and support future business growth.

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

R&D Cost — This Year

0.0

R&D Cost — Last Year

0.0

R&D Cost — 2 Years Ago

0.0

Assets Used in the Business

Permanent Assets — Description

The Company’s Key Fixed Assets ,The company’s key fixed assets used in business operations as of December 31, 2025, are detailed in the financial statements attached as Appendix 4, as follows:

1) Land, Buildings, and Equipment

As of December 31, 2025, the details and net book value of the company's land, buildings, and equipment, as presented in the company's financial statements, are as follows:

Assets

Ownership Characteristic

Net Book Value (Million Baht)

1.Land1

Owner

306.26

2.Buildings and Improvements

Owner

507.63

3.Tools and medical instruments

Owner

28.19

4.Office equipment and supplies

Owner

95.95

5.Vehicles

Owner

3.47

6.Assets during installation and construction in progress

Owner

1.49

Total Net Book Value

942.99

As of 31 December 2025, the Company owns a land plot under Title Deed No. 13449, with a total area of 2 rai, 2 ngan, and 83 square wah, located in Bukkhalo (Bang Sai Kai), Thon Buri District (Bangkok Yai), Bangkok. The land is currently being used for the construction of the hospital building.


2) Investment property

Investment Properties as of December 31, 2025, are detailed as follows:

Assets

Ownership Characteristic

Net Book Value (Million Baht)

Obligation

Land
AESTHETIC CONNECT PUBLIC COMPANY LTD.

Location : Bang Sai Kai Subdistrict, Fang Nuea, Khlong San District (Bang Lamphu) Bangkok 10600
Land : 385 square wah, Title Deed No. 1917

Owner

88.70

None


3) Right–of–use assets

As of 31 December 2025, the list and net book value of the Company's right-of-use assets as shown in the company's financial statements, the details are as follows:

Assets

Objective

Net book value (Million Baht)

Right of use (cost)

Less accumulated amortization

Net Book Value (Million Baht)

Office building

For use in conducting business

53.68

(53.68)

0.00

Vehicles

For use in conducting business

2.46

(1.66)

0.80

office supplies

For use in conducting business

1.57

(0.38)

1.91

Medical equipment

For use in conducting business

2.76

(0.23)

2.53

Total Net Book Value

60.47

(55.95)

4.52

4) Software Usage Rights

As of 31 December 2025, the items and net book value of the Company's software usage rights. As shown in the company's financial statements, the details are as follows:

Assets

Net Book Value (Million Baht)

Computer software cost price

0.95

Less : Accumulated amortization

(0.85)

Net book value

0.10

Permanent Assets — Appraisal

AssetOwnershipObligationAppraisal Value
LandOwnernone88.69

Intangible Assets — Description

As of December 31, 2025, the details and net book value of the company’s intangible assets, as reflected in the company’s financial statements, are as follows:

Assets

Net Book Value (Million Baht)

Computer program royalties, cost price

7.61

Less : Accumulated amortization

(1.69)

Net book value

5.92

Has Subsidiaries Investment Policy (Y/N)

Yes

Subsidiaries Investment Policy — Description

Aesthetic Connect Co., Ltd. (Public) ("the Company") has an investment policy, which includes the governance of its subsidiaries and associates. The Company will invest in businesses that are related, complementary, or provide benefits and support to the Company's operations, while considering the returns for all stakeholders. This is aimed at strengthening the stability and performance of the Company. Furthermore, in governing the operations of its subsidiaries and associates, the Company's Board of Directors will consider appointing qualified representatives with appropriate experience in the related business of the invested company as directors of the subsidiaries and associates. This is to ensure that the Company can govern the operations of its subsidiaries and associates as if they were part of the Company. The Company places great importance on having a good management system that is transparent and auditable, as it helps protect the interests of the Company's investments. The Company, therefore, requires its representatives to manage the subsidiaries and associates in the best interests of the Company, while ensuring compliance with the relevant laws governing the operations of the subsidiaries and associates. Additionally, the appointment of representatives as directors in the subsidiaries and associates will be in proportion to the Company’s shareholding in these entities. The Company ensures that its subsidiaries have an appropriate and sufficient internal control system to prevent potential fraud, as well as a clear operational system to ensure that there are adequate and reliable systems for disclosing significant transactions according to established criteria on a continuous basis. The Company also establishes mechanisms for auditing these systems within the subsidiaries, allowing the internal audit team and independent directors to have direct access to the information. The results of the audits will be reported to the executive committee or the Board of Directors to ensure that the subsidiaries consistently adhere to the established operational systems. The Company will closely monitor the performance and operations of its subsidiaries and associates, including overseeing the disclosure of related transactions and ensuring the proper collection and recording of data and accounts for audit by the Company. Regular reports will be made to the executive committee or the Board of Directors for continuous planning and setting goals for future operations.

Marketing Policy & Competition

Reporting Mode

3117

Marketing Policy (Overall)

Marketing Strategy

During the past year, the Company implemented its marketing policy with a focus on achieving sustainable growth alongside strengthening its brand image as a high-quality and standards-driven aesthetic surgery provider. The Company emphasizes effective access to target customers, building trust, and continuously enhancing customer experience. To achieve these objectives, the Company has adopted an integrated marketing strategy covering both online and offline channels, as outlined below:

Strategy 1: KOL, Influencer, and Celebrity Marketing
The Company leverages Key Opinion Leaders (KOLs), influencers, and celebrities to communicate its brand effectively to target audiences. By utilizing the credibility and image of these individuals, the Company enhances consumer trust, accelerates purchasing decisions, and continuously increases followers and engagement across its platforms.

Strategy 2: Pricing Strategy
The Company adopts a flexible pricing strategy tailored to different customer segments, including general customers, customers who provide reviews or content, and pricing based on the expertise and experience of physicians.

Strategy 3: Customer Retention
The Company places strong emphasis on retaining its existing customer base by encouraging repeat purchases. This is achieved through the use of customer data analysis (CRM Analysis) to deliver personalized experiences, such as recommending services or content aligned with individual customer preferences.

Strategy 4: Value-Based Marketing
The Company focuses on long-term brand value creation by emphasizing sustainability and social responsibility. Through marketing communications and activities that promote social awareness, the Company strengthens consumer trust and broadens brand acceptance.

Strategy 5: Brand Awareness Strategy
The Company aims to enhance brand awareness through a variety of media channels, including television, news websites, and out-of-home (OOH) media. This approach enables the Company to reach target audiences across multiple touchpoints and reinforces a strong and memorable brand presence in the market.

Strategy 6: Expanding Customer Target
The Company plans to expand its customer base by developing new products and services to meet increasingly diverse customer needs. Key approaches include:

  • Expanding services tailored to male customers

  • Targeting younger generations with high growth potential

  • Adjusting marketing and branding strategies to align with the behaviors of younger consumers

  • Strengthening branding efforts to attract younger customer segments

  • Expanding into international markets, particularly in Southeast Asia, including Malaysia, Singapore, and Indonesia

Service Capacity

As of December 31, 2025, Teeraporn Hospital has six surgical operating rooms, with a maximum combined service capacity of 21,900 hours per year.


Target Customer Characteristics

The company's service recipients are aged 20 and above, with middle to high income levels. They can be categorized into three groups based on their cosmetic surgery needs:

Customers aged 20-30 years – This group primarily seeks double eyelid surgery and rhinoplasty.

Customers aged 30-45 years – These customers have strong purchasing power and diverse cosmetic surgery needs. The most common procedures include double eyelid surgery, rhinoplasty, brow lift, canthoplasty (outer eye corner lift), and in some cases, facelift surgery to address concerns about facial wrinkles.

Customers aged 45 and above – This group has high purchasing power and often experiences issues such as wrinkles, drooping eyelids, sagging brows, or hair loss. They typically seek procedures such as facelift surgery, forehead lift, and fat grafting to restore facial volume and reduce sagging due to aging.


Distribution Channels

At present, the Company operates under the name “Teeraporn Hospital,” a 5-storey building located at 549 Somdet Phra Chao Taksin Road, Samre Subdistrict, Thonburi District, Bangkok 10600, with an approximate usable area of 9,918 square meters.

In addition, the Company distributes its services through agency/partner channels, consisting of individuals or juristic persons who are interested in aesthetic procedures and have customer bases to refer to Teeraporn Hospital. The Company has clearly defined qualifications and compensation structures for such agents. However, the Company has a policy prohibiting directors, executives, related persons, or persons with vested interests in the Company from acting as its agents.

Communication Channels

Offline Communication Channels
Customers or interested individuals can contact the Company directly at Teeraporn Hospital or via the central telephone number to obtain preliminary information and schedule appointments with physicians.

Online Communication Channels
The Company has increasingly developed its online communication channels to enhance accessibility and provide educational content on facial aesthetic procedures. Most customers contact the Company through its online platforms, such as the official website and social media channels including Facebook, Instagram, and LINE Official Account. These channels are convenient, fast, and aligned with customer behavior, as most customers conduct prior research before making decisions. This includes reviewing aesthetic procedures on social media, evaluating physicians’ reputations, comparing the advantages and disadvantages of different hospitals or clinics, and considering preliminary pricing for procedures of interest.

Having a strong presence across social media platforms enhances interaction and engagement between Teeraporn Hospital and its customers. In addition, online communication channels serve as effective marketing tools, enabling the Company to reach its target audience efficiently through both mass advertising and targeted campaigns.

As of December 31, 2025, the Company’s number of followers across its online communication channels is as follows:

Platform

Number of Followers (Accounts)

Facebook

560,000

YouTube

168,000

LINE Official

84,000

TikTok

87,900

Instagram

22,400

The dissemination of media and advertisements through various channels of Teeraporn Hospital is subject to the supervision of the Department of Health Service Support. The Company has obtained approvals for advertisements or announcements related to healthcare facilities for online media, including its website, YouTube, TikTok, Instagram, LINE, Facebook, and Google My Business.

In addition, prior to publication, the Company ensures that all advertisements are reviewed for compliance with the Notification of the Department of Health Service Support regarding rules, procedures, conditions, and fees for advertising or announcements related to healthcare facilities B.E. 2562 (2019), Chapter 2, Clause 8.

Industry & Competition (Overall)

Over the past year, the aesthetic surgery and aesthetic medicine industry has remained highly competitive, driven by the increasing number of operators, including aesthetic clinics, specialized hospitals, and new market entrants. This has resulted in greater market diversity and more choices for consumers.

Competition in the industry extends beyond pricing and encompasses multiple dimensions, including service quality, physicians’ expertise, medical technology, healthcare standards, as well as brand image and credibility. Operators have increasingly focused on specialization to differentiate themselves and enhance their competitive capabilities.

In addition, marketing competition has intensified, particularly through the use of digital media, social media, and KOLs/influencers to effectively reach target audiences. As a result, brand awareness and consumer trust have become critical factors influencing purchasing decisions.

At the same time, consumers are placing greater emphasis on safety, natural-looking results, and overall service experience. This has led operators to continuously elevate their service standards.

In terms of international markets, Thailand remains one of the key hubs for medical tourism in Southeast Asia, attracting customers from neighboring countries such as Malaysia, Singapore, and Indonesia. However, these countries are also increasingly developing their own aesthetic industries, leading to rising competition at the regional level.

Industry Outlook and Future Competitive Landscape

Looking ahead, the aesthetic surgery industry is expected to continue growing, supported by factors such as increasing awareness of personal appearance, the aging society, advancements in medical technology, and the expansion of younger customer segments. Key trends shaping future competition include:

  • Increasing competition in quality and specialization
    Operators will place greater emphasis on developing specialized expertise to differentiate their services and meet specific customer needs.

  • Technology and innovation as key competitive drivers
    This includes advanced medical technologies, data analytics for customer insights, and the application of AI in both marketing and service delivery.

  • Growing importance of digital marketing and branding
    Social media, KOLs/influencers, and content marketing will play an increasingly significant role in building credibility and reaching target audiences.

  • Consumer shift toward quality and long-term value
    Customers will prioritize safety, healthcare standards, and treatment outcomes over price alone.

  • Rising regional competition
    Countries in Southeast Asia continue to develop their aesthetic industries, requiring Thai operators to enhance their standards to remain competitive.

  • Expansion of niche markets
    Opportunities exist in segments such as male customers, younger generations, and international clients, which are expected to drive future growth.

In summary, while the aesthetic surgery industry continues to grow, competition is becoming increasingly intense. Operators must continuously adapt their strategies in terms of service quality, differentiation, technological adoption, and brand development to maintain competitiveness and respond effectively to future market changes.

Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

Procurement of Physicians and Medical Personnel

Physicians and medical personnel are the core of the Company’s facial aesthetic surgery business, as all procedures require professional knowledge, expertise, and experience. The Company therefore places great importance on recruiting and selecting high-quality personnel to support business growth and maintain high service standards.

The Company utilizes various recruitment channels for medical personnel, including the Company’s website, job recruitment platforms, and referrals within professional medical networks (word of mouth). As of December 31, 2025, the Company had the following medical personnel:

  • 36 physicians

  • 15 nurses and nurse assistants

The Company has a rigorous recruitment and hiring process to ensure that all personnel possess proper qualifications and valid professional licenses in accordance with legal requirements and certifications from relevant authorities. Comprehensive background checks are conducted, including verification of medical degrees, medical licenses, specialist certifications, training certificates, and work experience, to prevent misrepresentation or unauthorized medical practice.

In addition, all physicians joining the Company, regardless of prior experience, are required to undergo training and knowledge development under the supervision of the Company’s senior medical team. This ensures alignment with the Company’s proprietary techniques and service standards, enabling consistent, high-quality, and internationally standardized patient care.

Procurement of Pharmaceuticals, Medical Supplies, and Equipment

The Company procures pharmaceuticals, medical supplies, and medical equipment from domestic distributors or authorized representatives in Thailand that are certified by the Thai Food and Drug Administration (FDA) or the U.S. Food and Drug Administration (US FDA), both of which are recognized at national and international levels. Key products include pharmaceuticals, medical supplies, sutures, implants, silicone for rhinoplasty, botulinum toxin (Botox), and dermal fillers.

All pharmaceuticals and medical supplies are stored in accordance with established standards, with regular quality checks and expiration date monitoring to ensure patient safety and product quality.

The Company also conducts continuous evaluation and review of its suppliers based on product quality, service standards, delivery performance, and overall service through a Vendor Evaluation process. Evaluations are summarized monthly based on product deliveries and annually on an overall basis. Relevant supervisors are responsible for approval, and suppliers with performance below the required standards may be removed from the Company’s approved vendor list.

The Company adopts a policy of diversifying its procurement sources by purchasing from multiple suppliers without exclusive agreements, thereby reducing dependency risks and enhancing operational flexibility.

In 2025, the Company made purchases from certain suppliers accounting for more than 10% of total procurement under the consolidated financial statements, including:

  • DKSH (Thailand) Limited, a leading global company specializing in the distribution of pharmaceuticals, medical supplies, and medical equipment

  • Zuellig Pharma Ltd., a major domestic distributor offering a wide range of pharmaceutical and medical products

The Company considers these partners to have strong operational capabilities, reliable service standards, and the ability to consistently respond to the Company’s requirements efficiently.

Nature of Business — Overview

Introduction

The Company operates a healthcare facility under the name “Teeraporn Hospital,” providing aesthetic surgery services to the general public through a team of specialized and experienced physicians with over 10 years of expertise. The Company emphasizes high-quality service delivery through its team of specialists, standardized medical equipment and instruments, and a strong focus on patient safety.

Through its commitment to service quality, the Company has built strong brand credibility and achieved high levels of customer satisfaction, enabling continuous business growth.

Projects Under Construction

Has Projects Under Construction (Y/N)

No

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Has Convertible Securities (Y/N)

No

Contents